End-of-day quote
Other stock markets
|
||
- USD | - |
05-21 | Lineage Cell Therapeutics, Inc. Announces Updates to 2nd Annual Spinal Cord Injury Investor Symposium | CI |
05-09 | Transcript : Lineage Cell Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024 |
Sales 2024 * | 12.22M 16.79M | Sales 2025 * | 5.87M 8.06M | Capitalization | 174M 238M |
---|---|---|---|---|---|
Net income 2024 * | -29M -39.84M | Net income 2025 * | -32M -43.96M | EV / Sales 2024 * | 14.2 x |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 29.6 x |
P/E ratio 2024 * |
-7.07
x | P/E ratio 2025 * |
-5.35
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.56% |
Latest transcript on BioTime, Inc.
Managers | Title | Age | Since |
---|---|---|---|
Brian Culley
CEO | Chief Executive Officer | 53 | 18-09-16 |
Jill Howe
DFI | Director of Finance/CFO | 48 | 22-11-13 |
Chief Operating Officer | - | 09-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Neal Bradsher
BRD | Director/Board Member | 58 | 09-06-30 |
Brian Culley
CEO | Chief Executive Officer | 53 | 18-09-16 |
Deborah Andrews
BRD | Director/Board Member | 66 | 14-04-10 |
1st Jan change | Capi. | |
---|---|---|
+40.80% | 53.67B | |
+36.02% | 38.86B | |
-8.05% | 38.76B | |
-8.98% | 27.27B | |
+10.69% | 25.91B | |
-16.21% | 20.29B | |
+31.00% | 12.78B | |
+28.51% | 12.18B | |
-1.67% | 11.96B |